Professor Craig Simmons (MIE, BME), co-lead at TRANSFORM HF, looks forward to providing students with an immersive training experience beyond his lab and into the communities where their innovations will be used. (Photo: Neil Ta)
A new partnership between the University of Toronto and the Ted Rogers Centre for Heart Research is forging new collaborations and designing new technologies to reimagine how high-quality, digital approaches to heart failure can be equitably delivered to all Canadians.
TRANSFORM HF will build, support and fund a community of multidisciplinary engineers, basic and data scientists, clinicians, and health experts to develop solutions that will help monitor and proactively treat people with heart failure in their own homes and empower them toward greater self-care.
Heart failure affects at least one million Canadians. Nine out of 10 die within 10 years, having experienced a reduced quality of life, frequent lengthy hospital stays, and chronic disruptions to jobs, relationships and family life.
New therapies are dramatically improving quality of life and survival in heart failure, and technology is capable of changing how the disease is managed, according to Dr. Heather Ross, a Ted Rogers Centre Scientific Lead who was recently appointed to the Order of Canada for her dedication to advancing cardiac care.
“Unfortunately, these therapies and approaches are underutilized and inaccessible to a lot of Canadians,” Ross says. “Our goal is to unite the right people in devising new medical and artificial intelligence technologies that will achieve equitable access to high-level care across our country’s vast geography.”
She and Professor Craig Simmons (MIE, BME) — also a Ted Rogers Centre Scientific Lead and director of the Translational Biology and Engineering Program — are co-leading TRANSFORM-HF.
“We will bring together the vast amount of technology developed at the University of Toronto and deploy it in new ways,” says Simmons. “Our engineers and scientists will help our clinical partners deliver expert care to remote locations and perform continuous monitoring to keep people with heart failure safe.”
He says that some of these innovations, like biosensors and remote monitoring tools, already exist — and others will be co-designed by experts in different fields, and by patients themselves.
“Technology is often developed in a bubble, so for our engineers and scientists to collaborate with patients on design will change everything,” says Simmons. “The ability to interact with end users early will help us create solutions that work more quickly and more smoothly.”
“In medicine we must do things with patients, not to patients,” adds Ross. “They are the ones who will use these technologies, and they can tell us if our ideas make sense, or how they can be tweaked.”
A key goal of the program is to build user-centered technology that can be adapted by any patient, in any environment, with any specific need.
The TRANSFORM HF team will devise a new era of biosensors that can be packaged and used by Canadians in any community. These include wearable sensors built into fabric — socks, patches, vests — that monitor clinically relevant vitals like heart rate, blood pressure, breathing patterns and fluid accumulation. They may include a mobile app whose special camera can assess blood flow below the skin, and tech that syncs with consumer products like the Apple Watch or Fitbit.
Simmons says the team will also conceive new ways of bringing diagnostics that are done in the lab to people’s homes. “Patients often have to travel for them and wait days for results,” he says. “What if we could give them a small device that, for instance, takes a pin prick of blood, runs a test, and produces results in 15 minutes? These microtechnologies already exist, but they haven’t been engineered to specifically focus on markers important for heart failure.”
Innovations like these can yield oceans of data, which may hold new signals that reveal the state of someone’s heart failure or the risk of it worsening. The machine learning component of TRANSFORM HF is about creating algorithms that can predict someone’s risk of hospitalization, and enabling clinicians to intervene early to help keep that person in a stable condition.
To make the mission sustainable, TRANSFORM HF plans on training graduate students, scientists and clinicians across disciplines, beyond the lab and into communities and homes where their innovations are to be used.
“An immersive training experience allows our students to see first-hand what the constraints are, what power is available, what internet connectivity is like, and who the people are that they are designing technology for,” says Simmons. “New innovations will be set up to make a true difference in people’s lives.”
This training also includes commercialization, as students and fellows will explore entrepreneurship and vital aspects of translating technology such as regulatory rules.
All of this will rely on brand new partnerships with patients and communities, at all stages of development.
“This is a special opportunity to co-create and test new inventions in a collaborative sandbox, and I expect it to build into a long-term funding model to create a pipeline of innovations in the heart failure space,” Simmons says.
“For decades, we’ve watched heart failure care evolve incrementally.” says Ross. “But with all stakeholders working together, we will generate ideas that allow for transformative changes in how we manage this complex disease. Instead of taking steps we can make leaps.”
– This story was originally published on the University of Toronto’s Faculty of Applied Science and Engineering News Site on May 6, 2021 by Jeff Jurmain
Mihai “Mishu” Duduta is joining the Department of Mechanical and Industrial Engineering as an Assistant Professor in Mechanical Engineering. He completed his PhD at Harvard University, with a thesis focused on novel dielectric elastomer actuators (DEAs) materials for soft robotic applications. Mishu joins us from the University of Minnesota – Twin Cities where he developed soft robotic tools for endovascular interventions as a medical devices innovation fellow. He is the Principal Investigator at MARB-L (Materials for Actuators, Robots & Batteries – Laboratory) which studies novel materials and processes to build actuators and batteries for the robots of the future.
Kathy Cheng
